Siga Technologies (SIGA) Income towards Parent Company (2010 - 2025)
Siga Technologies' (SIGA) quarterly Income towards Parent Company came in at -$6.4 million in Q3 2025, down 573.67% on a YoY basis from $1.3 million in Q3 2024, and down 117.95% quarter-over-quarter from $35.5 million in Q2 2025.
Analysis
Siga Technologies (SIGA) Income towards Parent Company (2010 - 2025) Analysis & Trends
Siga Technologies (SIGA) has reported Income towards Parent Company for 16 consecutive years, with -$6.4 million the latest figure, recorded in Q3 2025.
- For the quarter ending Q3 2025, Income towards Parent Company fell 573.67% year-over-year to -$6.4 million; the trailing twelve-month figure through Sep 2025 stood at $74.5 million (down 13.05% YoY), and the FY2024 full-year result was $59.2 million, down 13.01% from the prior year.
- Income towards Parent Company retreated to -$6.4 million in Q3 2025 per SIGA's latest filing, from $35.5 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $73.4 million in Q4 2021 and bottomed at -$6.4 million in Q3 2025.
- Historically, Income towards Parent Company has averaged $13.6 million across 5 years, with a median of -$258928.0 in 2021.
- The sharpest annual moves came in 2023 and 2025: Income towards Parent Company soared 9000.73% in 2023, then slumped 573.67% in 2025.
- Over 5 years, Income towards Parent Company stood at $73.4 million in 2021, then sank by 101.11% to -$811794.0 in 2022, then jumped by 9000.73% to $72.3 million in 2023, then tumbled by 36.67% to $45.8 million in 2024, then tumbled by 113.91% to -$6.4 million in 2025.
- According to Business Quant data, Income towards Parent Company over the past three periods registered -$6.4 million, $35.5 million, and -$370415.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn |
| 10 | Siga Technologies | 220.19 Mn | 65.22 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -6.37 Mn |
| Jun 30, 2025 | 35.47 Mn |
| Mar 31, 2025 | -370,415.00 |
| Dec 31, 2024 | 45.76 Mn |
| Sep 30, 2024 | 1.34 Mn |
| Jun 30, 2024 | 1.80 Mn |
| Mar 31, 2024 | 10.28 Mn |
| Dec 31, 2023 | 72.26 Mn |
| Sep 30, 2023 | -393,066.00 |
| Jun 30, 2023 | -2.88 Mn |
| Mar 31, 2023 | -917,677.00 |
| Dec 31, 2022 | -811,794.00 |
| Sep 30, 2022 | 33.04 Mn |
| Jun 30, 2022 | 1.99 Mn |
| Mar 31, 2022 | -361,049.00 |
| Dec 31, 2021 | 73.38 Mn |
| Sep 30, 2021 | -3.11 Mn |
| Jun 30, 2021 | -258,928.00 |
| Mar 31, 2021 | -1.73 Mn |
| Dec 31, 2020 | 20.16 Mn |